FindTrial
Sign In

Clinical value of metagenomic second-generation gene sequencing technology for pathogenic microorganism identification and drug sensitivity detection in early diagnosis of peritoneal dialysis-associated peritonitis

Clinical value of metagenomic second-generation gene sequencing technology for pathogenic microorganism identification and drug sensitivity detection in early diagnosis of peritoneal dialysis-associated peritonitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070995
Enrollment
Unknown
Registered
2023-04-28
Start date
2023-04-15
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal dialysis-associated peritonitis

Interventions

experimental group:Metagenomic second generation gene sequencing
Control group:Traditional in vitro culture

Sponsors

Guangdong Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: There are no age or gender differences in patients with PDAP

Exclusion criteria

Exclusion criteria: Patients who could not provide informed consent or were unwilling to participate in this study

Design outcomes

Primary

MeasureTime frame
Peritoneal dialysis white blood cell count;—

Secondary

MeasureTime frame
The sensitivity and specificity of next generation sequencing technology in the diagnosis of PAPD;The detection rate of pathogenic microorganisms in PAPD by next generation sequencing technology;The detection time limit of PAPD pathogenic microorganisms by next generation sequencing technology;—

Countries

China

Contacts

Public ContactYeZhiming

Guangdong Provincial People's Hospital

yezhiming@gdph.org.cn+86 13826161678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026